文献速递肥胖与代谢综合征糖尿病性腺与生殖内分泌

减少代际肥胖与糖尿病风险

Reducing intergenerational obesity and diabetes risk.
PubMed 文献 · Diabetologia · 2021-01-06

本文为叙述性综述,总结产前临床试验经验并讨论孕前临床试验的新证据。产前干预使孕期增重减少约1 kg、妊娠糖尿病降低20-30%、巨大儿减少20-40%,但对后代其他结局影响有限;孕前试验多针对不孕超重/肥胖女性,减重3-9 kg并改善糖稳态,但后代结局证据不足。

要点

  • 产前干预可减少孕期增重、妊娠糖尿病和巨大儿,但对后代其他结局影响有限。
  • 孕前干预可减重并改善糖稳态,但对后代肥胖或糖尿病风险尚无获益证据。
  • 应优先开发可推广的孕前干预策略,关注高风险和资源匮乏人群。

核心结论

  • 亟需促进育龄女性健康的策略以应对肥胖和糖尿病的代际传递。
  • 产前干预对后代结局影响有限,孕前干预对后代肥胖或糖尿病风险尚无获益证据。
  • 应优先开发可推广的孕前干预策略,尤其针对高风险和资源匮乏人群。

研究设计与样本

  • 叙述性综述,总结多项产前临床试验并讨论孕前临床试验的新证据。

主要发现

  • 多数产前干预试验使孕期增重减少约1 kg,妊娠糖尿病降低20-30%,巨大儿减少20-40%,但对后代出生时及之后其他结局影响很小或没有影响。
  • 孕前干预试验几乎均在不孕的超重或肥胖女性中设计,以改善受孕或活产率,而非在多样人群中降低代际风险。
  • 孕前干预在干预结束时减重3-9 kg并改善糖稳态和胰岛素抵抗标志物,但效应是否持续至受孕尚不清楚。
  • 极少数研究报告后代出生时及之后的结局,迄今无证据表明对后代肥胖或糖尿病风险有益。

临床怎么用

  • 临床应重视育龄女性孕前健康管理,尤其针对超重/肥胖及不孕人群。
  • 产前干预可考虑用于减少孕期增重、妊娠糖尿病和巨大儿,但需告知对后代其他结局影响有限。
  • 未来研究应优先开发可推广的孕前干预,纳入多样人群并严格评估后代结局。

局限性

  • 孕前干预试验多针对不孕的超重或肥胖女性,外推至一般人群受限。
  • 孕前干预效应是否持续至受孕尚不明确。
  • 极少数研究报告后代结局,缺乏对后代肥胖或糖尿病风险的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To address the intergenerational transmission of obesity and diabetes, strategies promoting the health of women of reproductive age appear to be urgently needed. In this narrative review, we summarise what has been learned from many prenatal clinical trials, discuss the emerging evidence from preconception clinical trials and highlight persistent gaps and critical future directions. Most trials tested prenatal interventions that resulted in a limited gestational weight gain of ~1 kg and reduced gestational diabetes by 20-30%. These interventions also reduced macrosomia by 20-40% but had little-to-no impact on other offspring outcomes at birth or beyond. Far fewer trials tested preconception interventions, with almost all designed to improve conception or live-birth rates in overweight or obese women with infertility rather than reduce intergenerational risks in diverse populations. Preconception trials have successfully reduced weight by 3-9 kg and improved markers of glucose homeostasis and insulin resistance by the end of the intervention but whether effects were sustained to conception is unclear. Very few studies have reported offspring outcomes at birth and beyond, with no evidence thus far of beneficial effects on offspring obesity or diabetes risks. Further efforts to develop effective and scalable strategies to reduce risk of obesity and diabetes before conception should be prioritised, especially for diverse and under-resourced populations at disparately high risk of obesity and diabetes. Future clinical trials should include interventions with high potential for dissemination, diverse populations, thorough maternal phenotyping from enrolment through to conception and pregnancy, and rigorous assessment of offspring obesity and diabetes risks from birth onwards, including into the third generation.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Sauder KA, Ritchie ND. Reducing intergenerational obesity and diabetes risk. Diabetologia. 2021. PMID: 33404682. doi:10.1007/s00125-020-05341-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。